ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI.1 The update is based on results from the TRIDENT-1 and Beamion LUNG-1 trials.2,3 “Together, these studies signal a move toward more effective, next-generation targeted therapies designed for both upfront...
Dave Levitan
Verified
As seen in:
Gravity Is Gone,
Medium,
MSN,
HuffPost,
The Guardian,
TIME,
USA Today,
Yahoo News,
Earther,
Gizmodo,
The Atlantic
and
bsky.app/profile/davelevitan.bsky.social
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Dave
Contact Dave, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack